Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The Recognition and Prevention (RAP) Program is conducting a research study comparing an
antidepressant, sertraline, alone versus in combination with a second-generation
antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts,
suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention
and social skills in adolescents.
Phase:
N/A
Details
Lead Sponsor:
Northwell Health
Collaborators:
Janssen Pharmaceutica N.V., Belgium Pfizer Stanley Medical Research Institute